CONGENITAL BLEEDING DISORDER
Clinical trials for CONGENITAL BLEEDING DISORDER explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL BLEEDING DISORDER trials appear
Sign up with your email to follow new studies for CONGENITAL BLEEDING DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with hemophilia b: Long-Lasting clotting factor shows promise
Disease control CompletedThis study tested a new medicine called nonacog beta pegol (N9-GP) in 54 children under 6 years old with severe hemophilia B. The goal was to see if it safely prevents bleeding episodes and reduces the risk of developing antibodies that block treatment. The drug is given regularl…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 17, 2026 13:55 UTC
-
New hope for kids with hemophilia: safer clotting treatment studied
Disease control CompletedThis study tested a new medicine called N8-GP in 124 young children (under 6 years old) with severe hemophilia A who had never been treated before. The goal was to see if it safely prevents and treats bleeding episodes. The medicine helps blood clot, reducing the risk of bleeds.
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 17, 2026 13:54 UTC
-
New hope for kids with hemophilia b: trial shows bleeding control
Disease control CompletedThis study tested a new long-acting clotting factor drug (NNC-0156-0000-0009) in 25 children with hemophilia B. The goal was to see if it safely prevents bleeding episodes. Children received regular infusions to replace the missing clotting factor. The drug helped control bleeds,…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 15, 2026 11:53 UTC